A Framework for Patient-Centered Outcomes Research

Similar documents
Research in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research

Presenters: Robin Newhouse Steven Goodman David Hickam

Clinically Meaningful Inclusion of Participants in Clinical Trials. David Hickam, MD, MPH Washington, DC April 9, 2015

Accelerating Patient-Centered Outcomes Research and Methodological Research

The Academy Capitol Forum: Meet the Experts. Diagnosing Which Health Treatments Improve Outcomes: A PCORI Overview and How to Get Involved

Introduction to the Patient- Centered Outcomes Research Institute

Welcome! Pragmatic Clinical Studies. David Hickam, MD, MPH Program Director Clinical Effectiveness Research. David Hickam, MD, MPH

Guideline Development At WHO

The PCORI Methodology Standards Academic Curriculum TEACHING GUIDE

PCORI s Role in Supporting CER

Progress from the Patient-Centered Outcomes Research Institute (PCORI)

Observational Studies and PCOR: What are the right questions?

Lia Hotchkiss: I'm Lia Hotchkiss and I'm with the Agency for Healthcare. Research and Quality. We are one of the 12 agencies part of the Department of

PCORI Funding Announcement: Assessment of Prevention, Diagnosis, and Treatment Options

Data and Safety Monitoring in Pragmatic Clinical Trials. Susan S. Ellenberg, PhD Greg Simon, MD, MPH Jeremy Sugarman, MD, MPH, MA

Treatment of Multiple Sclerosis

The PCORI Methodology Report is undergoing final revisions to reflect the updated standards. The PCORI Methodology Report. PCORI Methodology Committee

Pragmatic Clinical Trials. Disclosure/Conflict of Interest. Learning Objectives 7/15/2015. Friedly: No disclosures

Pros and Cons of Clinical Trials vs. Observational Studies. Beth Devine PCORP Summer Institute July 14, 2015

CLOSED. PCORI Funding Announcement: Assessment of Prevention, Diagnosis, and Treatment Options

Implementation Science: Evidence to Action. Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University

Nature and significance of the local problem

Objectives. Information proliferation. Guidelines: Evidence or Expert opinion or???? 21/01/2017. Evidence-based clinical decisions

Chapter 2 Comparative Effectiveness Research

David O. Meltzer* Opportunities in the Economics of Personalized Health Care and Prevention

Comparative Effectiveness in Health Care Reform. Carrie Hoverman Colla, Ph.D. Dartmouth Medical School Norris Cotton Cancer Center

Pragmatic Trials and Comparative Effectiveness Research (CER) Sharon Straus Christine Hunter Russ Glasgow

Patient-Centered Measurement: Innovation Challenge Series

Pragmatic Trials and Comparative Effectiveness Research (CER) Sharon Straus Russ Glasgow

Framework and Action Plan for Autism Spectrum Disorders Services in Saskatchewan. Fall 2008

DP Program 2 National Comprehensive Cancer Control Program. Objective Reviewer s Tool March 2017

Volunteering in NHSScotland Developing and Sustaining Volunteering in NHSScotland

in Non-Profit Organizations Serving

Beyond the intention-to treat effect: Per-protocol effects in randomized trials

Note: Staff who work in case management programs should attend the AIDS Institute training, "Addressing Prevention in HIV Case Management.

Instrument for the assessment of systematic reviews and meta-analysis

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014

EER Assurance Criteria & Assertions IAASB Main Agenda (June 2018)

Making sense of Implementation

South Lanarkshire Council. Autism Strategy. Action Plan. Update April 2014

BACKGROUND + GENERAL COMMENTS

Product Makes Perfect

A Framework for Optimal Cancer Care Pathways in Practice

Health care guidelines, recommendations, care pathways

CONSORT 2010 checklist of information to include when reporting a randomised trial*

PrEP and Local Health Departments: Building the Infrastructure

Task Force Finding and Rationale Statement

Varenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks?

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018

Strategic Operational Research Plan February 13, Scientific Office Digestive Health Strategic Clinical Network

NCCIH s New Approach to Funding Clinical Trials Informational Webinar. April 18, 2017

Estimands and Their Role in Clinical Trials

Live WebEx meeting agenda

Understanding How the U.S. Preventive Services Task Force Works USPSTF 101

INTRODUCTION. Evidence standards for justifiable evidence claims, June 2016

CADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs

Outcome Research Coding Protocol. Coding Studies and Rating the Level of Evidence for the. Causal Effect of an Intervention

Bringing Value to Research: Engaging Patients and Caregivers in Palliative Care Research. Susan Enguidanos, PhD

Selecting a research method

Advancing Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation Day 2

Designing Pharmacy Practice Research

PCORI s Hepatitis C Workshop. Arlington, VA October 17, 2014

Integrating Quality Measures for RA into Your Practice: Optimizing Patient Care Using Your Own Data

Business Contributions to Setting New Research Agendas: Business Platform for Nutrition Research (BPNR)

Request for Proposals

Planning for Action at the Local Level

World Health Organisation: Clinical research in traditional and complementary medicine

Ontario s Narcotics Strategy

A Brief Introduction to Bayesian Statistics

Ministry of Children and Youth Services. Follow-up to VFM Section 3.01, 2013 Annual Report RECOMMENDATION STATUS OVERVIEW

Understanding How the U.S. Preventive Services Task Force Works USPSTF 101

Domain 2 for Chronic Disease Prevention and Control

WHO/MSD/MSB 00.2a. Framework Workbook. Framework Workbook

Perinatal Mental Health: Racial Disparities and Rural Mental Health Needs

EPIC. Purpose of Evaluation EXECUTIVE SUMMARY PILOT PROGRAM EVALUATION PROGRAM SERVICES

THEORY OF CHANGE FOR FUNDERS

Behavioral Interventions in Public Health

Pragmatic Trials: What the Heck Are They and Why Should You Care?

IMPORTANCE OF AND CRITERIA FOR EVALUATING EXTERNAL VALIDITY. Russell E. Glasgow, PhD Lawrence W. Green, DrPH

Managing Values in Science and Risk Assessment

Public Health Masters (MPH) Competencies and Coursework by Major

New NCCIH Funding Opportunities for Natural Product Clinical Trials. May 9, 2017

Are the likely benefits worth the potential harms and costs? From McMaster EBCP Workshop/Duke University Medical Center

Seeing the Forest & Trees: novel analyses of complex interventions to guide health system decision making

PCORI Funding Announcement: Pragmatic Clinical Studies and Large Simple Trials to Evaluate Patient-Centered Outcomes

Update from IMI PREFER: Patient preferences in benefitrisk assessments during the medical product lifecycle

E11(R1) Addendum to E11: Clinical Investigation of Medicinal Products in the Pediatric Population Step4

Definition. Synonyms 9/23/2010. Trials for which the hypothesis and study design are formulated based on information needed to make a decision

Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care

8/5/2017. Disclosure to Participants. What is PCORI? Outline. To Test or Not To Test. What is PCORI? THE MONITOR TRIAL

Systematic Reviews and Meta-analysis

PROPOSED WORK PROGRAMME FOR THE CLEARING-HOUSE MECHANISM IN SUPPORT OF THE STRATEGIC PLAN FOR BIODIVERSITY Note by the Executive Secretary

Current Quality Measurement Priorities and Challenges in the Medical Environment

FREE IN-DEPTH TRAINING

Post-Market Applications of Benefit- Risk Assessment!

Overview and Comparisons of Risk of Bias and Strength of Evidence Assessment Tools: Opportunities and Challenges of Application in Developing DRIs

Topic 1: What Are Embedded Pragmatic Clinical Trials?

Ethics Guidelines for HIV Prevention Research

Improving Access to High Quality Hospice Palliative Care

Systematic Reviews and Meta- Analysis in Kidney Transplantation

Transcription:

A Framework for Patient-Centered Outcomes Research David H. Hickam, MD, MPH Director of Research Methodology, PCORI Baltimore, MD August 9, 2016

Session Faculty Disclosures David H. Hickam, MD, MPH No relevant commercial interests No additional disclosures

Goals for this Presentation Review PCORI s model of patient-centered outcomes research Describe our approach for ensuring that research projects provide results that are useful for decision makers Address the strategies behind the PCORI Methodology Standards Address how new research can provide results that are applicable to diverse patient populations

What is PCORI? Established by Congress as part of the Patient Protection and Affordable Care Act Our mandate is to develop a program of comparative clinical effectiveness research Research evaluating and comparing health outcomes and the clinical effectiveness, risks, and benefits of 2 or more medical treatments or services Improved clinical evidence for decision makers Patient centered outcomes research $400 million/year for new projects

What is PICOTS? The Population that is studied The Intervention that is delivered to some patients The Comparator that other patients receive The important patient Outcomes that are assessed The Timing of when outcomes are assessed The study s clinical Setting

The PCORI Methodology Standards Guidance on the design and conduct of comparative effectiveness research Defined as minimal requirements for good research 47 specific standards grouped in 11 categories General domains Ensuring that the research questions are important Engaging participation of patients and research partners Ensuring data validity Specifying appropriate data analyses

What is Evidence-based Information? Clinical evidence: valid data about the outcomes experienced by patients who receive specific clinical interventions The clinical characteristics of the population are well defined and comparable to that of the patients for whom the evidence will be applied The clinical interventions are well defined and reproducible The study measures the right outcomes: those which are important to patients and their clinicians

What is the Starting Point of Comparative Effectiveness? Examine the choices people make about the options for managing a disease Consider how compelling it is to make a choice among these options Consider how the need to compare these options could inform the focus of new research Heterogeneity of the patient population Understanding the important benefits and harms Clarity about gaps in the current evidence base Engagement with partners facilitates these steps

Choosing a Study Design: The Problem of Comparability of Groups Confounding: systematic differences between the patients receiving alternative interventions Randomization is the best solution but has limitations To include sufficient heterogeneity of the patient population, sample sizes must be quite large Initiatives to streamline the conduct of clinical trials and improve efficiency Studies using observational designs can permit evaluation of treatment effect heterogeneity PCORI Methodology Standards Causal inference Heterogeneity of treatment effects

Choosing the Right Outcomes Value of engagement with clinical and patient partners Identify the most important benefits and harms Patient reported outcomes Can be tailored to those outcomes that are important to patients May require significant infrastructure to obtain these measures Issues of validity of measurement instruments Timecourse of measurement: is the follow-up sufficiently long?

Overview of the PCORI Methodology Standards The Methodology Committee created 47 Methodology Standards, which fall into 11 categories..

The report contains four types of stories, each with a different focus. The Methodology Report Includes Patient Stories

The Standards are Reasonable and Rigorous Are minimal standards for performing comparative effectiveness research. Are intended to provide helpful guidance to researchers and those who use research results. Reflect generally accepted best practices. Provide guidance for both project protocols and reporting of results. Are used to assess the scientific rigor of funding applications. Context of research should drive use of the standards. 16

1: Standards for Formulating Research Questions RQ-1 Identify gaps in evidence RQ-2 Develop a formal study protocol RQ-3 Identify specific populations and health decision(s) affected by the research RQ-4 Identify and assess participant subgroups RQ-5 Select appropriate interventions and comparators RQ-6 Measure outcomes that people representing the population of interest notice and care about

2: Standards Associated with Patient-Centeredness PC-1 Engage people representing the population of interest and other relevant stakeholders in ways that are appropriate and necessary in a given research context PC-2 Identify, select, recruit, and retain study participants representative of the spectrum of the population of interest and ensure that data are collected thoroughly and systematically from all study participants PC-3 Use patient-reported outcomes when patients or people at risk of a condition are the best source of information PC-4 Support dissemination and implementation of study results

3: Standards for Data Integrity and Rigorous Analyses IR-1 Assess data source adequacy IR-2 Describe data linkage plans, if applicable IR-3 A priori, specify plans for data analysis that correspond to major aims IR-4 Document validated scales and tests IR-5 Use sensitivity analyses to determine the impact of key assumptions IR-6 Provide sufficient information in reports to allow for assessment of the study s internal and external validity

4: Standards for Preventing and Handling Missing Data MD-1 Describe methods to prevent and monitor missing data MD-2 Describe statistical methods to handle missing data MD-3 Use validated methods to deal with missing data that properly account for statistical uncertainty due to missingness MD-4 Record and report all reasons for dropout and missing data, and account for all patients in report MD-5 Examine sensitivity of inferences to missing data assumptions, and incorporate into interpretation methods and

5: Standards for Heterogeneity of Treatment Effects HT-1 State the goals of HTE analyses HT-2 For all HTE analyses, pre-specify the analysis plan; for hypothesisdriven HTE analyses, pre-specify hypotheses and supporting evidence base. HT-3 All HTE claims must be based on appropriate statistical contrasts among groups being compared, such as interaction tests or estimates of differences in treatment effect. HT-4 For any HTE analysis, report all pre-specified analyses and, at minimum, the number of post-hoc analyses, including all subgroups and outcomes analyzed

Are there Other important Issues that are not Directly Addressed in the Methodology Standards? How to select the best study design to fill an evidence gap: the tradeoff between efficiency and the strength of evidence Power and the risk of Type 2 errors: determining the necessary sample size How to determine length of follow up: the issue of Timing Bias of the research team: the desire to prove superiority of a particular clinical practice

What are Pragmatic Clinical Studies? External validity: assessing whether the results of clinical research are applicable to other patient populations There are many consideration when planning a new study. Conducting studies in real world populations: diversity of the study s participants Fidelity of delivery of the intervention Assessing outcomes: tradeoffs between direct data collection and using available data about the clinical outcomes A more pragmatic study is not always a better study

Going back to PICOTS Research partnerships help in planning several important issues The Population that is studied The Intervention that is delivered to some patients The Comparator that other patients receive The important patient Outcomes that are assessed Researchers need to plan for other issues: The Timing of when outcomes are assessed: how long is long enough? The study s clinical Setting: external validity and pragmatic approaches

Conclusions Useful comparative effectiveness research requires careful planning Clarity about the clinical decision that is addressed Identification of an important evidence gap Adherence to best practices: Methodology Standards Both randomized controlled trials and observational studies can provide valuable evidence Planning and carrying out a study is hard This research is a partnership between researchers and clinical/patient partners

Contact Us www.pcori.org info@pcori.org

Thank You David Hickam, MD, MPH Director of Research Methods dhickam@pcori.org